entertainment -WSS

entertainment

author：knowledge 2025-09-05 04:56:33 - browse：33

LONDON — AstraZeneca said on Monday that a new lung cancer treatment outperformed standard-of-care chemotherapy in a trial, but investors found the results less impressive than anticipated, sending company shares down in early trading.

Based on an interim analysis of a Phase 3 trial, the company said that the drug, datopotamab deruxtecan, led to improvement in progression-free survival in patients non-small cell lung cancer, a primary endpoint of the study. There was also a positive early trend on overall survival, with Susan Galbraith, AstraZeneca’s oncology leader, describing the results as “compelling evidence for the potential role” that the drug could play for patients.

But investors had been hoping for a clearer signal of benefit. Analysts noted that despite the success in progression-free survival, it was not described as a “clinically meaningful” improvement, which, as J.P. Morgan analysts wrote, “we believe the market would have liked to have seen.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Peter Hotez and the public health issue of online harassment
Next article： Readout Newsletter: Illumina, CRISPR, Regeneron

WSS

People can get long Covid without testing positive for virus: Study

U.K. officials, researchers try to ease path for bespoke genetic treatments

Abortion policy in the spotlight at Republican debate

California store owner shot dead in dispute over displaying Pride flag: Police

Cancer, immunology, HIV research ensnared in fetal tissue politics

Can U.S. cancer drug shortages be fixed?

Wikipedia

entertainment

focus

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

National associations that represent hospice owe an apology

DIEP, the 'gold standard' of breast reconstruction, is under threat

Can U.S. cancer drug shortages be fixed?

Continuity nursing helped my family in our darkest PICU moments

Yancopoulos of Regeneron works to expand Dupixent success

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

FDA advisory panel to debate high blood pressure devices

DIEP, the 'gold standard' of breast reconstruction, is under threat

Adam's Take: Intra

hotspot

CRISPR technology availability, affordability needs to be expanded

Novo Nordisk to buy Cardior, building up pipeline of heart drugs

FDA advisory panel to debate high blood pressure devices

What Kate Middleton's cancer revelation might teach the world

PBMs are inflating the cost of generic drugs. They must be reined in

Can U.S. cancer drug shortages be fixed?

entertainment

entertainment

leisure time

focus